EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI), the pioneer in
2D/3D orthopaedic medical imaging, announced its financial reporting
schedule for 2014 today.
Financial publications will be released after market close. This
schedule is indicative and subject to change.
For further information about the Company or EOS®, the first full-body,
low dose 2D/3D imaging system, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and
patented medical imaging system, based on technology that enabled George
Charpak to win the Nobel Prize for Physics. The Company is authorized to
market the system in 31 countries, including the United States (FDA),
Japan, Canada, Australia and the European Union (EU). Backed by an
installed base of 75 sites and more than 400,000 imaging sessions, EOS®
benefits from worldwide recognition within the global medical community.
As of December 31, 2012 the Group posted 2012 consolidated revenue of
€9.42 million and employs 70 people including an R&D team of
25 engineers. The Group is based in Paris and holds three subsidiaries
in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and
offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext ParisISIN:
FR0011191766 - Ticker: EOSI
Next press release: Annual results 2013 on January 22, 2014 (after
[ Back To NFVZone's Homepage ]